Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.49 |
| ▸ | BRD4 | O60885 | 6/20 | 0.45 |
| ▸ | JAK1 | P23458 | 6/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | JAK2 | O60674 | 7/20 | 0.45 |
| ▸ | JAK3 | P52333 | 6/20 | 0.45 |
| ▸ | TYK2 | P29597 | 4/20 | 0.45 |
| ▸ | RET | P07949 | 3/20 | 0.45 |
| ▸ | FLT3 | P36888 | 3/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 5/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | PLK4 | O00444 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263728 | 0.89 | EGFR (0.45) | SYKBRD4JAK1JAK2JAK3 | |
| SCHEMBL12278793 | 0.87 | EPHB4 (0.49) | SYKBRD4JAK1HDAC1JAK2 | |
| SCHEMBL265873 | 0.87 | JAK3 (0.60) | SYKBRD4JAK1HDAC1JAK2 | |
| SCHEMBL12109324 | 0.80 | BRD4 (0.41) | SYKBRD4JAK3CDK2CDK4 | |
| SCHEMBL17915959 | 0.78 | TTBK1 (0.47) | SYKBRD4CDK2AURKASRC | |
| SCHEMBL17915643 | 0.78 | BRD4 (0.47) | SYKBRD4JAK1JAK2JAK3 | |
| SCHEMBL301633 | 0.78 | TTBK1 (0.45) | SYKBRD4JAK2JAK3CDK2 | |
| SCHEMBL265485 | 0.77 | BRD4 (0.72) | BRD4CDK2EGFRFGFR4CDK9 | |
| SCHEMBL270593 | 0.75 | TTBK1 (0.45) | SYKBRD4JAK1JAK3CDK2 | |
| SCHEMBL12279055 | 0.74 | TTBK1 (0.50) | SYKBRD4CDK2AURKASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | SYK 59/4885BRD4 156/4885JAK1 6/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | SYK 281/4885BRD4 142/4885JAK1 4/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | SYK 281/4885BRD4 142/4885JAK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.